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ABSTRACT
Introduction: Over 70% of all hospital admissions
have a peripheral intravenous device (PIV) inserted;
however, the failure rate of PIVs is unacceptably high,
with up to 69% of these devices failing before
treatment is complete. Failure can be due to
dislodgement, phlebitis, occlusion/infiltration and/or
infection. This results in interrupted medical therapy;
painful phlebitis and reinsertions; increased hospital
length of stay, morbidity and mortality from infections;
and wasted medical/nursing time. Appropriate PIV
dressing and securement may prevent many cases of
PIV failure, but little comparative data exist regarding
the efficacy of various PIV dressing and securement
methods. This trial will investigate the clinical and cost-
effectiveness of 4 methods of PIV dressing and
securement in preventing PIV failure.
Methods and analysis: A multicentre, parallel
group, superiority randomised controlled trial with 4
arms, 3 experimental groups (tissue adhesive,
bordered polyurethane dressing, sutureless securement
device) and 1 control (standard polyurethane dressing)
is planned. There will be a 3-year recruitment of 1708
adult patients, with allocation concealment until
randomisation by a centralised web-based service. The
primary outcome is PIV failure which includes any of:
dislodgement, occlusion/infiltration, phlebitis and
infection. Secondary outcomes include: types of PIV
failure, PIV dwell time, costs, device colonisation, skin
colonisation, patient and staff satisfaction. Relative
incidence rates of device failure per 100 devices and
per 1000 device days with 95% CIs will summarise the
impact of each dressing, and test differences between
groups. Kaplan-Meier survival curves (with log-rank
Mantel-Cox test) will compare device failure over time.
p Values of <0.05 will be considered significant.
Secondary end points will be compared between
groups using parametric or non-parametric techniques
appropriate to level of measurement.
Ethics and dissemination: Ethical approval has
been received from Queensland Health (HREC/11/
QRCH/152) and Griffith University (NRS/46/11/HREC).
Results will be published according to the CONSORT
statement and presented at relevant conferences.
Trial registration number: Australian New Zealand
Clinical Trial Registry (ACTRN); 12611000769987.
INTRODUCTION
Peripheral intravenous devices (PIVs) are the
most commonly used medical device world-
wide: almost all hospital patients need one
or more to receive intravenous treatment.1 2
The failure rates of these devices are
unacceptably high, affecting up to 69% of
patients receiving therapy.3–7 Of these, 10%
Strengths and limitations of this study
▪ This is the first large-scale, independent multi-
centre randomised controlled trial to investigate
the efficacy and cost-effectiveness of peripheral
intravenous device (PIV) dressing and secure-
ment methods to prevent PIV failure.
▪ The trial examines a novel tissue adhesive
securement method for the first time in PIVs.
▪ This is a pragmatic trial, with PIVs inserted and
cared for by general staff in two adult hospitals,
not specialist teams or researchers.
▪ Microbiology end points will be analysed by
blinded scientists, and infection outcomes
assigned by a blinded infectious disease special-
ist outcome assessor. It will not be possible to
blind the dressing and securement intervention/
control from clinical staff, patients or research
nurses.
▪ Patients with existing skin problems, severe dia-
phoresis or frail skin are excluded from the
study, so results will not be generalisable to
these groups.
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simply fall out, despite having a dressing in place, with
patients then unable to receive treatment.5 Other PIVs
become painful or occluded and must also be replaced.
Such failure rates for an essential device are unaccept-
able and indicate that current dressings and securement
methods are inadequate, with much failure potentially
preventable with improved effective dressing and
securement.
Intravenous devices
About 90% of all vascular catheters are PIVs.8
Approximately 330 million PIVs are sold in the USA
alone each year.9 The external component of PIVs
require securement to the skin, with dressings and other
securements used to ensure that PIVs do not dislodge
and fall out, or move out of the vein and into surround-
ing tissue. Effective securement also minimises PIV
micromotion within the vessel, which irritates the vein
wall, causing inﬂammation presenting as pain, swelling
and PIV occlusion/inﬁltration.6 10 Micromotion may also
encourage skin bacteria to enter the PIV wound, causing
infection risk.
PIV failure
PIV failure occurs when the PIV can no longer be used
for treatment. Failure can be mechanical (dislodgement,
occlusion, inﬁltration), vascular (phlebitis) or infectious
(localised or bloodstream infections). PIV failure is an
important detrimental patient outcome that causes: (1)
interruptions to medical treatment and compromised
patient safety from lost vascular access; (2) painful phle-
bitis lasting for days or weeks at the PIV site, even after
removal; (3) potentially increased hospital length of stay
and mortality from PIV-associated bloodstream infection;
(4) additional needlesticks for replacement of PIV inser-
tions; and (5) replacement of PIVs in poorer quality
veins with exponentially higher risk of device failure and
need for central venous catheter insertion with even
greater infectious and other complication risks.11 12
Studies have reported high PIV failure rates, up to
69%.3–7 Inadequate dressing and securement is most
likely a factor in most PIV failures, with one study report-
ing that 71% of PIVs are inadequately secured.13
PIV dressing and securement
Despite its obvious importance, the study of effective
approaches to PIV dressing and securement has received
little attention.10 14 The earliest PIV dressing and secure-
ment was with simple tape or gauze and tape, with
plastic ﬁlm dressings becoming prominent in the
1980s.15 16 An early systematic review found plastic ﬁlms
to have higher infection risk than gauze and tape17 and
this spurred the development of the modern standard
polyurethane dressings (SPU) which are transparent
and semipermeable to oxygen, carbon dioxide and
water vapour.18 SPUs (eg, Tegaderm, 3M, St Paul or
IV3000, Smith & Nephew, Hull) have been standard
care for many years.19 In contrast with gauze and tape
dressings that are generally limited to short-term use,
SPUs allow visualisation of the insertion site and can be
left in place for up to 7 days if not soiled, loose or
wet.18 20 Suturing is not recommended as this increases
infection.20
Two new approaches to PIV dressing and securement
are bordered polyurethane (BPU) and sutureless secure-
ment devices (SSDs). BPUs retain the central polyureth-
ane component of SPUs with an added adhesive border
of foam or cloth (eg, Veni-Gard I.V. stabilization
Dressing, CONMED, Utica). One BPU manufacturer
(Tegaderm IV Advanced Securement Dressing, 3M, St
Paul, Minnesota, USA) reports that it has nearly twice
the pull-out force of SPU; however, there are scant inde-
pendent data on the effectiveness of BPUs.21 22 For
example, Needham and Strehle22 studied four different
BPU and SPUs, but the small sample size of 78 pre-
cluded statistical comparisons. BPU use is not yet wide-
spread, most likely due to increased costs over SPU and
lack of convincing data to support its implementation.
SSDs are used in conjunction with SPUs. They have a
large adhesive padded footplate with a PIV locking or
gripping clasp (eg, StatLock, Bard Access Systems,
Murray Hill; Grip-Lok, Vygon, Ecouen; Hubguard,
Centurion, Williamston). They are designed to reduce
movement, dislodgement, kinking and ﬂow impedance.10
A manufacturer-initiated, non-randomised study report-
ing data from 10 164 patients in 63 hospitals observed
that PIV failure reduced from 71% to 17% (p<0.001)
when securement was with SSD (and SPU) compared
with tape (and SPU), with signiﬁcant estimated cost
savings.23 A manufacturer-sponsored and analysed rando-
mised controlled trial (RCT; N=302) reported BPU to
have a 25% lower purchase price than SSD, and PIV
failure rates at 96 h of 52% for SSD, and 62% for BPU.1 It
remains unclear whether BPU or SSD has more beneﬁt
over traditional less expensive SPU dressings.
Tissue adhesive
Another potential product to assist with PIV securement
is tissue adhesive (TA) which is medical grade ‘super-
glue’ (cyanoacrylate). TA is used mainly to close skin
lacerations and wounds as an alternative to sutures or
staples, but also to repair gastric varices, inguinal
hernias, bones, tendons and retinal detachments.24 25
TA has haemostatic properties that may reduce postin-
sertion bleeding, haematomas and associated infection
risk. The use of TA to secure vascular access devices has
only been reported in two case reports.26 27 In these, TA
was completely successful in securing approximately 100
epidural and central venous devices with no skin reac-
tions or mechanical problems reported.26 27 Epidural
fallout was reduced from 12% to 4%, but little data were
provided on study methods or sample characteristics.26
The pull-out force required to dislodge PIVs secured
with SPU, BPU, SSD, TA or no dressing (control) was
tested in an experimental model.28 Compared with no
dressing, neither SPU nor BPU signiﬁcantly increased
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the pull-out force required to dislodge the PIV, although
this may have been an underpowered comparison. In
contrast, TA and SSD signiﬁcantly increased the pull-out
force, and TA resulted in a bond which was four times as
strong as an SPU dressing.28 The bactericidal properties
of TA include inhibition of all Gram-positive organisms,
including methicillin-resistant Staphylococcus aureus, the
predominant organisms in PIV infections.29 We demon-
strated that TA inhibits S. aureus and S. epidermidis both
under the TA, and down the PIV tunnel at 18 and 72 h
dwell time.28 Given the strong results from non-
controlled clinical reports and in vitro work, TA may
assist in avoiding PIV failure by reducing pistoning and
accidental removal, with additional beneﬁts being infec-
tion prevention and comfort for patients.
PIV dressing and securement remains a poorly
researched area of patient safety and has been identiﬁed
as a priority area for improvement.23 Previous research is
limited by small samples, non-randomised designs and the
manufacturer’s involvement. Moreover, there has been no
speciﬁc study comparing the cost-effectiveness of different
PIV dressing and securement approaches, which vary
widely in purchase price but may be more cost-effective if
they reduce PIV failure. This study will test the efﬁcacy,
cost-effectiveness and acceptability to patients and profes-
sionals of TA (used with SPU), BPU and SSD (used with
SPU), against current care (SPU alone) to assist policy-
makers with decision-making about the best dressing and
securement choice for patients with PIVs.
METHODS AND ANALYSIS
The study will be a multicentre, parallel group superior-
ity RCT with four arms: three experimental groups (TA,
BPU and SSD) and one control (SPU). There will be a
3-year recruitment of 1708 adult patients from two large
teaching hospitals in south-east Queensland, Australia.
Comprehensive assessment of effectiveness, cost-
effectiveness and acceptability will be performed in line
with the Medical Research Council model for evaluating
complex interventions.30 This will include smaller quali-
tative components including staff survey and focus
groups. The protocol is V.1 dated 6 October 2011.
Outcome measures
Primary outcome
1. PIV failure: composite of any unplanned PIV
removal, prior to completion of therapy. This
includes: dislodgement (complete), occlusion (PIV
will not infuse, or leakage occurs when ﬂuid
infused), phlebitis (score of 2 or more of pain/ten-
derness, redness, swelling, purulence and/or a palp-
able cord) or infection (laboratory-conﬁrmed local
or bloodstream infection).20 31
Secondary outcomes
1. PIV and dressing/securement dwell time: Time in
hours from insertion/application until removal.
2. Costs: Direct costs to the hospital for device manage-
ment, including costs of PIV replacement in addition
to the effects of dressing choice (randomised
product and any additional tape or reinforcements).
3. Types of PIV failure will be analysed as secondary out-
comes (dislodgement, occlusion, phlebitis and
infection).
4. PIV colonisation (>15 colony forming units (cfu))
from a purposive 10% subset of devices.32
5. Skin colonisation (>15 cfu) from a purposive 10%
subset of patients.32
6. Patient (overall with product) and staff satisfaction
(with removal) ranked on a 10-point scale.
Setting and sample
Patients will be recruited from the medical and surgical
areas, and critical care departments at the Royal Brisbane
and Women’s Hospital and the Princess Alexandra
Hospital, Queensland, Australia. Only one PIV will be
studied per patient. The study hospitals together have
approximately 500 000 separations per annum. Inclusion
criteria are: ≥18 years of age; requires a PIV for clinical
treatment; and the duration of clinical treatment with the
PIV is expected to be longer than 24 h. Exclusion criteria
will be: non-English speaking patients without inter-
preter; PIV to be inserted through burnt or diseased skin
(eg, blisters, sunburn, bruising, rash or skin infections);
severe diaphoresis; known allergy to any study product;
terminal/palliative care patients; current skin tear or clin-
ician believes patient is at high risk of a skin tear; or previ-
ously enrolled in the study.
Sample size and study power
We hypothesise a difference (reduced failure rate) for
each of the three alternative treatments against control.
For each, we will measure difference in outcomes for
pairs of treatments (ie, group (G)1 (SPU—controls) vs
G2 (TA); G1 vs G3 (BPU); G1 vs G4 (SSD)—that is, in
turn the three alternatives versus the control). Sample
sizes were calculated for three inequality tests of two pro-
portions. Our recent trial of 3283 patients in the same
study hospitals showed failure rates of 40% using SPU.33
We hypothesise that TA, BPU and SSD will each reduce
failure by an absolute proportion of 10%, therefore to
30%. A 10% absolute difference in PIV failure incidence
was also observed in a previous study of SSD and BPU,
and would be clinically important to detect.1 23 PASS
(Power Analysis & Sample Size system, NCSS, Utah) was
used to calculate the sample required to reduce the
40% device failure rate (controls) to 30% in each of the
three experimental groups with 90% power at p=0.05.
This results in each group requiring 388 patients, that is,
a total of 1552 PIVs. We will add 10% to allow for poten-
tial attrition, therefore 1708 patients in total.
Recruitment, randomisation, allocation concealment
and blinding
Research nurses (ReNs), not clinicians, will screen
patients on a daily basis, gain informed consent and
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perform randomisation for each patient at the time of
study entry. Randomisation will be via a centralised web-
based service provided by Grifﬁth University. This will
ensure full compliance with best practice standards for
computerised randomisation generation and allocation
concealment until study entry. Randomisation will be
stratiﬁed by hospital site, and in a 1:1:1:1 ratio between
the four study groups. Block randomisation will be used
with random variation in block sizes to further ensure
allocation concealment. PIV dressings are not amenable
to blinding of patients, clinical staff or ReNs. However,
there is no suggestion in the literature or our practice
that clinical staff or patients would sabotage medical
devices to favour one group. This is an independent aca-
demic study, with no product manufacturer having any
involvement in the research.
Insertion and care of the PIV dressings and securements
PIVs will be inserted, and dressing and securements
applied by clinical nurses, medical staff or the ReNs
using standard policies in place throughout Queensland
Health. The study sites do not have dedicated intraven-
ous teams to perform insertions, although there are a
small number of intravenous nurse consultants who
provide education and undertake surveillance. Extensive
education will be delivered to staff on how to apply, care
for and remove the study products. All study products
will be changed weekly or earlier if they are not clean,
dry and intact, as recommended by the Centres of
Disease Control (CDC).20 Strips of non-sterile tape on
the intravenous tubing will be permitted in all groups as
per usual practice, and this will be documented.
Data collection
The ReNs, all of whom have had study-speciﬁc database
training, will directly enter data in the clinical areas
using portable password-protected electronic devices
with a purpose-built RedCAP database and form-based
interface. All data are de-identiﬁed at this point and
only identiﬁable within the database by speciﬁc study
number. The master list of participants will be kept sep-
arately from the study database in a different password-
protected computer program at the hospital sites.
Patient characteristics collected by ReNs at baseline will
be: age, sex, estimated weight category, diagnostic group,
dominant limb, comorbidities, length of stay, immuno-
deﬁciency, current infection, intravenous therapy
(including antimicrobial), skin integrity, skin type, and
the presence of a wound, drain, tracheostomy or intes-
tinal stoma. PIV characteristics collected will be: device
type, insertion site, PIV gauge, side of insertion, clinical
area/ward, inserter discipline, insertion difﬁculty,
initial/subsequent PIV, skin preparation (including dis-
infectants and clipping), use of gloves for insertion, and
the addition of extension tubing and injection ports.
After PIV removal, the following data will be collected:
reason for PIV removal, dwell time, infusates given, oral
antibiotic therapy, number of additional vascular access
devices in place, phlebitis signs and symptoms, level of
consciousness, mobility level, delirium status, hospital
length of stay and hospital mortality. Clinical staff will
order blood and PIV cultures from patients suspected of
PIV-related infection as per usual practice and the ReNs
will access the results. Clinically instigated cultures will
be performed by blinded scientists in the hospital
laboratories. Routine culturing is unnecessary and leads
to comparable infection rates as those performed on
clinical suspicion.10 The ReNs will visually inspect PIVs
daily and assess for phlebitis (redness, pain/tenderness,
swelling, purulence, palpable cord or vein streak); dress-
ing integrity (including any dressing change and/or
addition of secondary securement products) and any
residue, rash, blister, itchiness or tearing of skin on
dressing removal (adverse event). At device removal, the
ReN will ask the patient (if able) about their satisfaction
with the dressing and securement on a 10-point scale
(0=completely dissatisﬁed, 10=completely satisﬁed). The
person removing the dressing will be asked to rate the
difﬁculty of removing the product (0=very difﬁcult,
10=very easy). A study manager (reporting to the chief
investigator) will audit data quality, completeness and
protocol adherence with site visits for initial training and
then for monitoring at least bimonthly. Since trial par-
ticipation is relatively short (approximately 1 week) and
participants will remain hospitalised, high rates of reten-
tion and follow-up are expected. A purposive sample of
150 clinical staff (about 10% of staff involved in the
trial) will be invited to participate in a brief researcher-
developed survey about study products and trial involve-
ment. Further, 10–15 key clinical and policy staff will be
invited to participate in a brief semistructured interview
about perceived barriers/enablers of implementation of
the results, using a nominal group technique.
Data analysis
The principal investigator, study manager and trial statis-
tician will have access to the ﬁnal data set. All rando-
mised patients will be analysed by intention to treat,
regardless of the treatment received. The patient will be
the unit of measurement, with only one PIV studied per
patient. Comparability of groups at baseline for risk of
device failure will be assessed. Relative incidence rates of
device failure per 100 devices and per 1000 device days
with 95% CIs will summarise the effectiveness of each
dressing and securement, and test for differences
between groups. Kaplan-Meier survival curves (with a
log-rank Mantel-Cox test) will compare device failure
over time. Secondary end points will be compared
between groups using parametric or non-parametric
techniques as appropriate. In addition to group, multi-
variate regression (Cox) models will test the association
between patient and device characteristics and device
failure (eg, age, PIV insertion site). Missing data will be
modelled for best-case and worst-case outcomes to assess
for potential effect on overall results. A per-protocol ana-
lysis will assess the effect of protocol violations. p Values
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of <0.05 will be considered signiﬁcant. We do not expect
effect sizes to vary between sites; however, variability will
be assessed and, if necessary, adjustment made in the
model, with consideration of potential institutional dif-
ferences in practice variables. Survey data will be
described and interview data thematically analysed for
issues that provide contextualisation of the RCT results,
and inform implementation of ﬁndings into practice.
Estimating cost parameters and cost-effectiveness
analysis
Direct costs to the hospital for device management will
be captured including purchase costs of dressings and
securements, any additional tape or reinforcements, and
the costs incurred by PIV failure (eg, PIV replacement
or antibiotics to treat PIV infections). Adverse event
costs will be obtained from hospital cost centres for
precise estimates, given the likely variability in costs
between participants, reasons for admission and hospi-
tals. Detailed resource use for dressing and securement
replacement will be recorded for 100 replacements
selected at random (25 per device per group).
Resources to be recorded include nurse/doctor time for
replacement, waiting times for treatment and equipment
(eg, dressings). The study will determine the hours of
nursing and medical time required for replacement,
wage costs per minute and the cost of treatments. These
data will be used to estimate total resource use and costs
for each of the groups over the study period. A cost ana-
lysis using analysis of covariance or non-parametric boot-
strapping techniques (dependent on the distribution of
the cost data) will be undertaken from the public hos-
pital perspective to compare mean total costs for the
four treatment groups. Explanatory clinical and demo-
graphic variables (in addition to group) will be
explored. A cost-effectiveness analysis will also be under-
taken to estimate the incremental cost of each study
product alternative per additional PIV failure avoided,
compared with SPU. This will indicate the device secure-
ment that would provide the best value for money if
implemented more widely in clinical practice.
Microbiological testing and end points
To further inform the infection outcomes, a substudy
(purposive 10%) will have ReNs take PIV tip and skin
cultures (from under the dressing) immediately after
PIV removal.13 These specimens will be transferred to
the laboratory, with skin swabs streaked onto non-
selective agar, and PIV tip segments roll-plated.32 After
24 h of incubation, plates will be examined for bacterial
colony counts. The plates will then be reincubated for
72 h to enable growth of slow-growing species. Species
identiﬁcation will be determined morphologically, bio-
chemically and, if required, genetically (eg, PCR and
sequencing). Samples will be scored for the presence of
bacteria, the total cfu and species present. The added
workload and cost mean this is not feasible for the
entire sample. For patients who consent, we will store
recovered microorganisms for use in potential future
infection control studies.
In vitro antimicrobial properties
We will also investigate the antimicrobial properties of
each dressing.34 These tests are similar to the minimum
inhibitory concentration evaluations for antibiotics.
A conﬂuent bacterial monolayer on the surface of solid
agar will be produced by plating liquid bacterial suspen-
sions. An aliquot of TA will be dropped onto one point of
the agar plate. We will do this for unpolymerised, semipo-
lymerised and fully polymerised TA. For SPU, BPU and
SSD, a 0.5 cm disc will be cut and laid on the plate, incu-
bated and the zone of inhibition determined. We will also
examine growth under each specimen. Bacteria asso-
ciated with PIV infection will be used (S. epidermidis,
S. aureus, Pseudomonas aeroginosa, Stenotrophomonas malto-
philia).35 36 A modiﬁcation of this method will also be
used to investigate bacterial migration between the
dressing and securement products and the agar surface,
modelling bacterial migration at the skin/PIV interface.
Proportions colonised between study groups will be com-
pared with non-parametric techniques.
ETHICS AND DISSEMINATION OF RESULTS
Ethical and safety considerations
The trial is registered with the Australian New Zealand
Clinical Trials Registry (ACTRN 12611000769987).
Written informed consent will be obtained from partici-
pants or representatives to participate in this trial, with an
additional option to consent for the data and specimens
collected to be stored and used in future infection
control studies. Consent can be withdrawn from the trial
participation for use of the study products and/or data
collection if participants change their mind. In these
cases, the trial products would be removed (if the partici-
pant requests) and replaced with SPU dressings. Serious
adverse events (deaths, ICU admissions, PIV-related
bloodstream infections) will be monitored and reported
to the Human Research and Ethics Committees (HREC).
Owing to the rapid recruitment expected in the trial,
there are no plans for interim analyses or safety data
monitoring beyond that reported to the HREC. The
study manager will communicate important protocol
modiﬁcations or clariﬁcations to relevant parties (investi-
gators, ReNs, HREC, trial registry).
Dissemination of results
The prevention of medical device failure, improved well-
being, hospital patient satisfaction and responsible use
of the health dollar are all of high interest to stake-
holders, including the general community. To dissemin-
ate results widely, the investigators will present results
locally and at relevant international meetings. The study
can be expected to be published in an inﬂuential
medical journal and rapidly translated into clinical
policies. Additional processes to promote research
Rickard CM, et al. BMJ Open 2015;5:e008689. doi:10.1136/bmjopen-2015-008689 5
Open Access
group.bmj.com on August 21, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
translation into practice will be sought, for example,
brief practical articles in professional newspapers.
DISCUSSION
PIV failure is a common problem and affects millions of
people each year. Improved dressing and securement is
likely to prevent many cases of PIV failure. However,
despite a high clinical need and the high costs to hospi-
tals for products given the signiﬁcant volume of use,
there is a paucity of studies reporting the efﬁcacy of alter-
native dressing and securement methods. Rigorous assess-
ment of the efﬁcacy and cost-effectiveness of PIV dressing
and securement methods is therefore needed to guide
clinical decision-making. If failure rates can be reduced
by 10%, this would prevent more than 30 million PIV fail-
ures and reinsertions in the USA each year alone, with
phenomenal associated reductions in health costs and
nursing/medical time.9 The results from this large RCT
will have a signiﬁcant impact on international health pol-
icies, decrease hospital budgets, reduce nursing/medical
workloads and improve patient experiences.
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